NEW YORK, July 27, 2026, 3:02 p.m. EDT. Gossamer Bio shares rose sharply after the company outlined its FDA filing strategy, but lingering questions over cash reserves and potential shareholder dilution persist.
- Shares of Gossamer Bio increased by 41% to $0.1917. The SPDR S&P Biotech ETF (NYSEARCA:XBI) was up 0.8%.
- Minutes from an FDA meeting back the filing of a seralutinib application in September. An outcome may be reached in the third quarter of 2027.
- Gossamer Bio reported preliminary cash of $57 million at the end of June, down from $99.2 million as of March 31.
Gossamer Bio Inc. NASDAQ:GOSS shares jumped 41% to $0.1917 as of 2:46 p.m. EDT on Monday. Earlier in the day, the stock reached a session high of $0.2134. U.S. stock markets were still trading.
The action came after receiving updated feedback from the U.S. Food and Drug Administration, which reduced the short-term risk of the filing being denied. However, it did not resolve the issue of whether approval would be granted.
The FDA has classified the statistical result and treatment effect of seralutinib as matters for review, not as obstacles to filing. Gossamer intends to file its application in September.
The filing is set to be based on data from the Phase 3 PROSERA trial. Gossamer intends to supplement it with results from the Phase 2 TORREY study and additional supportive analyses. Pending acceptance, the submission may result in an FDA decision in the third quarter of 2027.
The capital changes were more involved. Gossamer has concluded its partnership with privately owned Chiesi Group, reacquiring global rights to seralutinib. Chiesi is set to pay Gossamer $5 million. Gossamer is not required to make any upfront payments.
Chiesi maintains global royalty and milestone entitlements up to a capped amount. Gossamer will preserve the majority of downstream economic interests and continue to oversee pricing, manufacturing, and commercialization activities. The previous arrangement for development cost-sharing will terminate.
Investors are considering regulatory developments while also factoring in a slimmer balance sheet:
| Measure | Latest reading | Comparison |
|---|---|---|
| Gossamer share move | $0.1917, gains 41.0% | XBI rises 0.8% |
| Trading volume | 255.5 million shares | Roughly 13.3 times the weekly average of 19.2 million |
| Cash and securities | Preliminary $57 million as of June 30 | $99.2 million at March 31; down 42.5% |
| Convertible-note principal | Roughly $84.1 million after exchange | $200 million pre-exchange; drop of 57.9% |
| New-note conversion price | Roughly $0.187 per share | Near Monday’s closing price |
The cash balance declined by about $42.2 million over the quarter. Gossamer spent $38.7 million on operations in the first quarter. The numbers are not directly comparable due to differences in payment timings and one-off expenses.
Debt relief offers some flexibility. The swap reduced principal by roughly $115.9 million, leaving $65.2 million in secured notes maturing in 2030 and $18.9 million in outstanding older notes.
Dilution acts as the counterbalance. At the starting conversion rate, the new notes account for approximately 348.7 million shares, representing 71% of the 488.8 million common shares listed as outstanding as of June 5. All conversions are still governed by the terms of the notes.
Gossamer Chairman and CEO Faheem Hasnain stated the company is “moving forward with a planned NDA submission” in September. The firm noted that final approval is subject to the FDA’s full review. Gossamer Bio Investor Relations
Seralutinib continues to have a challenging track record in clinical trials. PROSERA boosted six-minute walking distance by 13.3 metres compared with placebo. The p-value reached 0.0320, not meeting the prespecified threshold of 0.025.
Approved therapies are already available in the PAH market, such as Winrevair by Merck & Co. Inc. NYSE:MRK and Tracleer by Johnson & Johnson NYSE:JNJ. Seralutinib will be required to demonstrate a positive overall benefit-risk balance during the assessment process.
Risks are still elevated. The FDA may turn down the filing or reject the approval. Gossamer had already cautioned there is significant doubt regarding its ability to remain a going concern. The company estimated that funding as of the end of March would support operations through early 2027. Shareholders have also approved a reverse stock split, with implementation anticipated in or just after the third quarter.
The next major catalyst will be the September submission. Following Monday’s rally, both financing terms and the risk of dilution could be just as significant as acceptance of the filing.
